

'era™ Tumor genomic profile

# Improved patient access

Identify appropriate therapies and monitor molecular residual disease (MRD) to help guide treatment decisions



## Affordable pricing and billing options

- Natera bills all commercial and government insurance plans (i.e. Medicare, Medicare advantage, Medicaid and private insurances)
- Majority of our patients will have zero out of pocket (OOP)
- Please note, Medicare patients are fully covered under the following scenarios:
  - With stage II/III colorectal cancer for Signatera testing
  - With solid tumors on immunotherapy for Signatera testing
  - With stages III/IV solid tumors for Altera testing
- For any remaining patient responsibility, Natera has robust financial assistance programs that can be offered to qualified patients to ensure the test is as affordable as possible

### How our testing process works



## Natera accepts all commercial and public insurances

We are committed to make testing as affordable as possible

#### **Medicare coverage**

### Signatera

X X X

×

X X

- Benefits include serial use of Signatera in patients with stages II/III colorectal cancer (CRC)<sup>1</sup>
- Benefits also include single time point use for patients with stages II/III colorectal cancer
- Medicare patients with stages II/III CRC are fully covered; other indications are welcome however an ABN may be required\*
- Patients on immunotherapy will be covered for serial use of Signatera

## Altera

Medicare patients diagnosed with solid tumors are fully covered if they meet one of these criteria: either recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; other stages are welcome however an ABN is required\*

Please note, Altera testing is covered only if the Altera NGS test has not been previously ordered for the patient's same primary diagnosis of cancer.

#### Commercial insurance

- We welcome all insurance plans
- We will work with patients so that cost is not a barrier for testing
- We offer an affordable cash pay rate for those patients who do not wish to use insurance

## Billing support services

#### **Compassionate Care Program**

At Natera, we understand that billing processes can be confusing. If a patient is uninsured or concerned about their ability to pay for testing, they can complete an online application or contact one of our Patient Coordinators at **signaterapc@natera.com** 

#### **Patient Coordinators**

Natera's Patient Care team will proactively reach out to patients after the test is ordered, and are available to answer questions related to Signatera.

- Individually dedicated patient coordinators
- Assist with billing process and pricing
- Financial Assistance

For questions or financial assistance, please contact Natera's Patient Coordinators.

Phone: **1.650.489.9050** Fax: **1.650.412.1962** Email: **signaterapc@natera.com** 

### For more information on Signatera's published studies, please visit: natera.com/oncology

1. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. *Nature*. 2017;545(7655):446-451. \*Please contact our Patient Coordinators for more information on when an ABN is required: **signaterapc@natera.com** 

13011 McCallen Pass, Building A Suite 100 | Austin, TX 787 | www.natera.com | 1.650.489.9050 | Fax 1.650.412.1962 This test was developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. © 2021 Natera, Inc. All rights reserved. 20210426\_NAT-8020282





